PUNE, India, November 2, 2016 /PRNewswire/ -- According to a new market research report "PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), by Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies) - Global Forecast to 2021", published by MarketsandMarkets, the global market is expected to reach USD 1,137.8 Million by 2021 from USD 690.6 Million in 2016, at a CAGR of 10.5% from 2016 to 2021. (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ) Browse 87 market data Tables and 65 Figures spread through 176 Pages and in-depth TOC on"PEGylated Proteins Market"http://www.marketsandmarkets.com/Market-Reports/pegylated-protein-market-19242378.htmlEarly buyers will receive 10% customization on this report. Increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing adoption of protein based drugs over non-protein based drugs are the primary growth drivers for this market during the forecast period (2016-2021). However, drug failure and recalls may hinder the growth of this market. The global PEGylated Proteins Market is segmented on the basis of products, protein type, application, and end-user. On the basis of product, the market is segmented into consumables and services. Of these, the consumables product segment accounted for the largest share of the global PEGylated Proteins Market in 2016. The large share of this segment can primarily be attributed to the increasing adoption of kit-based PEGylation products. On the basis of end-user, the market is segmented into pharmaceutical & biotechnology companies, CROs, and academic research institutes. Of these, the pharmaceutical & biotechnology company's end-user segment accounted for the largest share of the global PEGylated Proteins Market in 2016, owing to increased R&D spending by pharmaceutical and biotechnology companies.